Dr Feingold’s experience in oncology and hematology will continue to drive the DSI’s current cardiovascular portfolio and shape its pipeline. He will also become a member of DSI’s executive committee, which is responsible for guiding the organization’s short- and long-term strategic and financial objectives.
Prior to joining DSI, Dr Feingold worked with Wyeth Pharmaceuticals, where he recently led oncology global clinical development. Prior to that, he was multi-therapeutic area head in global medical affairs with responsibility for the hematology, oncology and central nervous system (CNS) franchises.
Dr Feingold, said: “I am excited to join Daiichi Sankyo and look forward to working with my colleagues to continue to build relationships with health care providers to improve medical care and enhance professional education. As we develop new and innovative therapies it will be important to ensure that critical safety and efficacy information is understood by practitioners, regulatory agencies, payors and patients. Medical Affairs plays a key role in communicating this information.”